Extracorporeal Hemadsorption versus Glucocorticoids during Cardiopulmonary Bypass: A Prospective, Randomized, Controlled Trial

Table 1

Patient and surgery characteristics at baseline.

Characteristic	Methylprednisolone (n = 20)	Cytosorb (n = 20)	Control (n = 20)	value
Preoperative
Age, years (median) [range]	66.5 (18.25) [43–80]	70.5 (26.5) [34–80]	71 (17.75) [31–85]	0.525/0.171/0.372
Male/female	13/7	14/6	14/6	0.736/0.736/1.000
Body surface area, m^2 (median) [range]^ASA	1.811 (0.206) [1.548–2.133]	1.962 (0.28725) [1.716–2.286]	1.97 (0.245) [1.652–2.257]	0.038/0.068/0.705
EuroSCORE II (median) [range]	1.985 (0.9925) [0.96–12.98]	2.26 (2.825) [0.96–10.43]	2.78 (4.645) [0.96–10.74]	0.579/0.203/0.645
LVEF, % (median) [range]	61.5 (14) [29–87]	60.5 (11.25) [30–80]	65 (20) [39–77]	0.249/0.683/0.414
Intraoperative
One valve surgery + CABG, M/F	5/3	0/3	6/3	0.077/0.749/0.038
More than one valve surgery + CABG, M/F	2/0	0/0	1/0	0.147/0.548/0.311
More than one valve surgery, M/F	1/3	4/2	1/2	0.465/0.677/0.256
Surgery of ascending aorta, M/F	1/1	5/0	4/0	0.212/0.376/0.705
Valve surgery + CABG + surgery of ascending aorta, M/F	1/0	1/0	0/0	1.000/0.311/0.311
Valve surgery + surgery of ascending aorta, M/F	2/0	3/1	1/1	0.376/1.000/0.376
Valve surgery + other procedures (ASD and RFA), M/F	1/0	0/0	1/0	0.311/1.000/0.311
Valve surgery + surgery of ascending aorta + other procedure (ASD and RFA), M/F	0/0	1/0	0/0	0.311/1.000/0.311
Anaesthesia time, min (median) [range]	358 (91.25) [249–563]	352.5 (124.25) [237–499]	335 (81.5) [258–528]	0.989/0.561/0.425
Surgery time, min (median) [range]	245.5 (74.5) [150–445]	252.5 (101.75) [153–388]	237 (59) [161–393]	0.766/0.457/0.317
Cardiopulmonary bypass time, min (median) [range]	150.5 (41.5) [90–240]	146 (68.5) [91–281]	127 (56.75) [90–238]	0.725/0.239/0.473
Aorta cross-clamping time, min (median) [range]	104 (43.5) [66–206]	105 (45) [56–244]	102 (43.5) [63–184]	0.882/0.482/0.725
Erythrocytes, mL (median) [range]	0 (308.75) [0–585]	0 (567.5) [0–1525]	0 (575) [0–1760]	0.495/0.176/0.748
Fresh frozen platelets, mL (median) [range]	0 (934.5) [0–1322]	527.5 (768) [0–1031]	503 (738.75) [0–1282]	0.346/0.616/0.415
Thrombocytes, mL (median) [range]	0 (0) [0–350]	0 (0) [0–300]	0 (0) [0–0]	0.971/0.317/0.317
Cell saver, mM (median) [range]	580 (520) [0–2927]	467 (358.25) [0–1147]	511.5 (305.25) [0–1000]	0.099/0.285/0.379
Fibrinogen, g (median) [range]	0 (2) [0–4]	1 (2) [0–3]	0 (2) [0–3]	0.834/0.482/0.558
Prothrombin complex concentrate, IE (median) [range]	0 (0) [0–3000]	0 (0) [0–500]	0 (0) [0–0]	0.264/0.076/0.317
Recombinant activated factor VII, mg (median) [range]	0 (0) [0–7]	0 (0) [0–0]	0 (0) [0–0]	0.317/0.317/1.000
Crystalloids, mL (median) [range]	1500 (500) [1000–2000]	1500 (1000) [1000–2500]	1000 (500) [1000–2000]	0.098/0.696/0.069
Colloids, mL (median) [range]	0 (0) [0–1000]	0 (0) [0–500]	0 (500) [0–500]	0.150/0.386/0.021
Postoperative
Postoperative mechanical ventilation, h (median) [range]	9.5 (11) [3–1257]	14.5 (11.75) [4–26]	8.5 (12.25) [5–29]	0.192/0.514/0.568
Length of stay (ITU), h (median) [range]	90.5 (132) [58–1932]	121 (77) [47–304]	117 (89.5) [64–407]	0.379/0.465/0.756
Length of stay (hospital), days (median) [range]	10 (9) [6–82]	13 (8.25) [6–30]	11 (11) [6–26]	0.497/0.644/0.625
New-onset atrial fibrillation	4	5	3	0.705/0.677/0.429
Worsening of renal function	0	0	1	1.000/0.311/0.311
Postoperative myocardial infarction	0	0	1	1.000/0.311/0.311
Postoperative delirium	0	2	0	0.147/1.000/0.147
Dressler syndrome	3	0	2	0.072/0.633/0.147
Tamponade	3	1	1	0.292/0.292/1.000
Thrombocytopenia	1	1	0	1.000/0.311/0.311
Infection	2	4	4	0.376/0.376/1.000
Without postoperative complications	7	6	4	0.736/0.288/0.465
30-day mortality	0	0	0	1.000/1.000/1.000
30-day readmission	2	3	3	0.633/0.633/1.000
1-year mortality	1	0	0	0.311/0.311/1.000

Data are shown as (median) and [interquartile range]. MP, methylprednisolone; CS, cytosorb; CO, control. value for comparisons of groups: (MP versus CS)/(MP versus CO)/(CO versus CS).